scholarly journals Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

2021 ◽  
Author(s):  
Martijn J. H. G. Simons ◽  
Valesca P. Retèl ◽  
Bram L. T. Ramaekers ◽  
Rogier Butter ◽  
Joanne M. Mankor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Whole Genome Sequencing ◽  
Diagnostic Test ◽  
Genome Sequencing ◽  
Small Cell ◽  
Whole Genome ◽  
Small Cell Lung ◽  
Clinical Diagnostic Test

scholarly journals Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer

2018 ◽  
Vol 5 (1) ◽  
pp. a002659
Author(s):  
Erica S. Tsang ◽  
Yaoqing Shen ◽  
Negar Chooback ◽  
Cheryl Ho ◽  
Martin Jones ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Whole Genome Sequencing ◽  
Clinical Outcomes ◽  
Genome Sequencing ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Whole Genome ◽  
Small Cell Lung

Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer

2020 ◽  
Vol 9 (18) ◽  
pp. 1301-1309
Author(s):  
Longfeng Zhang ◽  
Xiaofang Zeng ◽  
Hongfu Cai ◽  
Na Li ◽  
Maobai Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Second Line ◽  
Small Cell Lung ◽  
The Cost ◽  
Quality Adjusted Life

Aim: To analyze the economic impact of nivolumab and chemotherapy in patients with non-small-cell lung cancer (NSCLC) who developed disease progression after platinum-containing dual-drug chemotherapy. Materials & methods: The partitioned survival model was used to analyze the cost-utility of two NSCLC treatments by nivolumab and docetaxel. The clinical data resulted from the Phase III clinical trial. The cost parameters were derived from our previous studies, and the utility parameters were derived from the literature. Results: The quality-adjusted life-years of nivolumab and docetaxel were 0.778 and 0.336. The lifetime direct medical expenses of nivolumab and docetaxel were US$44,707.17 and US$12,826.72. The incremental cost–effectiveness ratio was $72,127.71/quality-adjusted life-year. Conclusion: The combination of chemotherapy, nivolumab is not a cost-effective choice in the second-line treatment of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document